Company history

Kirin’s origins are foreign. In 1870 the American William Copeland built Japan’s first beer brewery, the Spring Valley Brewery, on the Yamate bluff in Yokohama, supplying the foreign settlements of Yokohama and Nagasaki and exporting to Shanghai and Saigon for about fifteen years. In 1885 prominent foreign residents and Japanese business leaders founded the Japan Brewery Company on the Spring Valley site and built the country’s first modern brewery; its beer, named “Kirin Beer,” went on sale in 1888. Made with German brewing technique and good imported malt, it stood out for quality and sold nationwide at a premium from the start — the quality-first legacy that a foreign-run brewery handed to the later Kirin.

In 1907 men from Mitsubishi, Meiji-ya and Nippon Yusen established Kirin Brewery Company, taking over Japan Brewery’s assets and engineers and moving management into Japanese hands. It was built on a division of labour — Kirin manufactured, Meiji-ya distributed, Mitsubishi supplied the capital — which spared it from being swallowed by the era’s giant mergers. Through the Taisho boom, wartime demand and Southeast Asian exports lifted the whole industry; Kirin added the Kanzaki (later Amagasaki) plant in 1918, a Sendai plant in 1923, and a new Yokohama plant at Tsurumi in 1926 after the Great Kanto Earthquake destroyed the Yamate works. In 1927 it dissolved Meiji-ya’s sole-agency arrangement, absorbed its beer-sales division and set up its own sales department — inheriting a foreign legacy and making it independent under Japanese capital and engineers, the backbone of Kirin’s later self-reliance.

The decisive break came in 1949: the anti-monopoly deconcentration law split Dai-Nippon Beer — which had held more than 70% of the prewar market — into Nippon Beer (later Sapporo) and Asahi. Kirin, which escaped the breakup, revived its Meiji-era Kirin trademark and faced the two new rivals with steadily rising demand. Before the war, on-premise sales had taken 70% of the market and Kirin could reach only households; afterwards the democratization of beer and rising incomes flipped the ratio toward home consumption — exactly the segment Kirin led — and that reversal, together with the structural advantage of having avoided the split, propelled its share.

On the supply side Kirin expanded hard, opening a Tokyo plant in 1953 ahead of rivals and pouring $255.6M (¥92bn) into capacity between 1950 and 1968 — a 24-fold rise in shipments against the industry’s 14-fold. Its market share, just 25% in 1949, reached about 50% from 1966 and, in December 1972, topped 60.1%. The specialty-dealer network passed 760 outlets, and by the late 1960s Kirin was the world’s second-largest brewer after Anheuser-Busch.

But a share above half brought its own ceiling. Antitrust scrutiny narrowed the room to grow by volume, and in 1975 Kirin drew up its “Showa 50 Structural Plan,” turning toward stable growth and diversification into soft drinks and food. Winning too well had produced a growth ceiling — and the same instinct to defend a dominant share began to harden into an organizational conservatism that would later show up as its slow answer to Super Dry.

Asahi’s Super Dry, launched in 1987, changed what drinkers chose, and Kirin’s share slid. Management first read it as a passing fad and could not bring itself to remake the taste of its flagship Lager: for a company with 60% of the market, changing the taste risked alienating the very customers it had, so “not changing” looked rational. Too much to protect made a nimble response hard — a textbook case later taught in management courses. Share fell to 48.5% in 1989, and in 2001 Kirin ceded the No. 1 position to Asahi, a fall from the top that forced a reckoning with the danger of depending on a single business.

The answer had, in fact, been seeded years earlier and off to one side. In 1982 Kirin decided to turn the fermentation and culturing technology it had built brewing beer toward bio-pharmaceuticals, setting up a drug-research lab and choosing not the mainstream of chemically synthesized medicines but the biologics fringe, where established makers ranked entry a low priority. It partnered with Amgen in 1984 to sidestep patent risk and launched the EPO drug Espo in Japan in 1990. The stable cash flow of beer underwrote the long research without demanding quick returns; in 2008 Kirin bought Kyowa Hakko Kogyo, formed Kyowa Kirin, and raised pharmaceuticals into a genuine second pillar alongside beer and beverages. A brewer growing a drug business into its second pillar was unusual even in Japan’s food industry — possible only because the strength of the core could fund a distant bet.

In 2011 Kirin Holdings bought Brazil’s second-largest brewer, Schincariol, for about $3.8B (¥304bn), chasing a market with a growing population and roughly 10% annual consumption growth. But almost at once it was pulled into a shareholder dispute among the founding family, and Brazilian price competition and a weak real compounded the problem; the internal family conflict that due diligence had missed hollowed out the returns. In December 2015 Kirin booked a roughly $1.2B (¥140bn) impairment and fell to its first net loss — a hard lesson that entering a growth market does not by itself create value. Out of it came a shift from pursuing scale to pursuing quality: a discipline of selecting and concentrating overseas businesses, and of not postponing the decision to withdraw.

With the overseas-beer expansion reined in — Kirin exited Myanmar in 2022 and pared back — the company leaned on the stable earnings of domestic beer and beverages while pushing toward the higher-value fields of pharmaceuticals and health science. In June 2024 it took Fancl fully private through a tender offer, five years after a 2019 capital alliance, judging that a partial stake could never fully integrate the research and sales channels it wanted; the aim was to fuse Kirin’s fermentation and bio technology with Fancl’s consumer reach and make health science a pillar of growth. That same year leadership moved to a two-headed structure under Isozaki Yoshinori as chairman and CEO and Minakata Takeshi as president and COO, and Kirin began, in reverse, to tidy the sprawl its acquisitions had created — selling out of overseas beer and even the amino-acids business of Kyowa Hakko Bio — declaring the structural reform done and the company moved into a “growth-realization stage.” A brewer redefining its very business domain around fermentation, carrying the technology of its core into new fields, is a growth path bound up with a company culture that runs back to before the war.